A team-based telehealth model produced outcomes equivalent to in-person care for patients with atopic dermatitis, according to an analysis reported by AJMC. For dermatology practices still sorting post-pandemic workflows, that equivalence finding matters more than the usual telehealth cheerleading. It suggests the debate can shift from "is virtual AD care safe?" to "how do we staff it?"

What did the model actually involve?

The key word is team-based. This was not a lone dermatologist staring at a webcam. The model distributed care across clinicians working collaboratively, with virtual visits standing in for the traditional office encounter. Atopic dermatitis, a chronic inflammatory condition requiring ongoing titration of topical and systemic therapy, is exactly the kind of disease where continuity — not procedural hands-on examination — drives results.

That distinction shapes who can replicate it. A solo practitioner doing one-off video visits is not running the same model. A group practice, or a health system with midlevel providers and dermatologists sharing panels, is.

What does this change for practices?

The practical question: what does outcome equivalence buy you? Two things.

First, capacity. AD follow-up visits consume a large share of clinic slots, and many involve assessment that a well-run virtual team can handle — itch and sleep reports, flare distribution from patient photos, medication adherence checks, refills. Freeing those slots moves in-person time toward procedures, skin-cancer management and diagnostic uncertainty.

Second, access. Eczema care is unevenly distributed geographically, and wait times for dermatology appointments are well documented. A team-based virtual pathway lets a practice reach patients who would otherwise delay care or land in urgent care with a steroid shot and no follow-up plan.

The caveats practitioners will ask about

Equivalence in a reported model is not a blanket guarantee for every panel. The finding applies to atopic dermatitis management, a visually assessable, longitudinally managed condition. It does not automatically extend to lesions requiring dermoscopy, biopsy or total-body skin exams — the in-person staples that telehealth cannot replace. Payer behavior is the other open variable. Reimbursement rules for telehealth have shifted repeatedly, and a model's viability depends on which virtual visit codes remain covered and at what rates in each state and payer contract. Practices building chronic-care telehealth around AD should anchor the business case on those coding and reimbursement specifics, not on outcomes alone.

Where this points

Expect team-based telehealth to move from pandemic stopgap to standing infrastructure for chronic inflammatory skin disease, with atopic dermatitis — and likely psoriasis follow-up next — as the proving ground. Practices that formalize the staffing model now, and lock in payer terms while equivalence data accumulates, will be the ones positioned when the next coverage decision lands.